Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're just embarrassing yourself pretending this isn't a scam that hoodwinks gullible suckers.
You had full FDA submission in 2017...what's changed?
https://www.otcmarkets.com/filing/html?id=12414685&guid=4td-kaJ6H_M4B3h#UEEC_EX991_HTM
"FDA Selects HemoStyp ® for CtQ Pilot Program
Henderson, Nevada – December 4, 2017 –United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the FDA’s new and innovative CtQ Pilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meeting with FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).
The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics of the device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the postmarket inspection. For pilot program participants, the FDA would forego conducting the standard PMA preapproval inspection, and a postmarket inspection focusing on the PMA applicant’s implementation of the critical to quality characteristics would be conducted instead.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner. This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html)
Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application – Expanded Indication submission with the US FDA-- continues to progress, and is in an advanced stage of review
About Premarket Approval Application Critical to Quality (PMA CtQ) Pilot Program
Top-quality medical devices help the FDA better protect and promote public health. And one of the top priorities for FDA’s medical devices center is a focus on quality.
More specifically, the FDA is working with stakeholders—industry, health care providers, patients, payers, and investors—to build a strong Case for Quality.
This program allows the FDA to identify device manufacturers that consistently produce high-quality devices. By doing so, we can better focus our resources helping other manufacturers raise their level of quality. This program also helps the FDA identify and promote practices that support consistent quality manufacturing, and align our regulatory, enforcement, compliance approaches with those practices.
The FDA launched the Case for Quality in 2011 following an in-depth review of device quality data and feedback from both FDA and industry stakeholders. The FDA’s analysis flagged certain widespread or common manufacturing risks that impact product quality. The review also showed manufacturers that focus on and manage those risks often become more productive, receiving fewer complaints, needing to open fewer CAPAs and investigations, and having lower quality-related product costs than their competitors.
In simple terms, the review identified that an investment in quality has long-term payoffs."
Means NOTHING…. We have a FULL FDA SUBMISSION!
Go ahead, try and pick that apart, douchie!
Looks like, once again, I am telling the truth. Butler Capital even lists him as working there. I'm just trying to clear things up so the marks for this Ponzi Scheme aren't mislead by pathological sociopaths. Certainly, you understand that, don't you dr5?
Next we visit Butler's website:
Brian Thom
Alternative Asset Sales for Butler Capital and Principal of Waveny Partners, Alternative Asset Management Firm
Previous Experience
Capital Placement Practitioner and Advisor to Corporate Clients for Butler Capital and Principal of Waveny Partners
Head of Corporate Finance for the Americas with Société Générale
Managing Director at FBR & Co. Leading M&A and equity capital raising transactions in the Energy sector
Global Mergers & Acquisitions group at JPMorgan
Master in Business Administration from McMaster University
The link tells a different story. Who should we believe; you or the link? It says Thom is an active broker at Butler Capital Partners.
https://brokercheck.finra.org/individual/summary/4231884
BUTLER CAPITAL PARTNERS (CRD# 114242)
2022 - Present (1 year)
Current Registration(s)
B
BUTLER CAPITAL PARTNERS (CRD#:114242)
151 Post Road Titus House, OLD WESTBURY, NY 11568
Registered with this firm since 11/11/2022
1. Brian Thom is a M&A executive who was with Societe’ General.
2. He maintains his broker license but is not an active broker.
3. He is fulfilling all contractual agreements as CEO of UHP.
You twist the truth to your narratives which shows what a dirtbag you are.
What specifically is not true? Is that not the address UHP gives as "headquarters" on their website? Do these links bother and trouble you? Name every employee and tell us their responsibilities? Tell us what has changed with the PMA's between 2017 and now?
You seem pretty upset for someone who owns stock in a wonderful company that does wonderful business. Why? Can't you just sit back and let the market respond to this wonderful product with wonderful sales? You should be on top of the world being a shareholder as you inform us you are.
This guy right here is in charge?: https://brokercheck.finra.org/individual/summary/4231884
He must be doing a lot as CEO of UHP while sitting behind the desk of a totally different company. And you say Beplate has nothing to do with it? Who picked this stockbroker to be "CEO"?
And at the other end of the country from Thom is UHP headquarters:
526 Commerce Circle, Suite 120 Mesquite, NV 89027
Nice Suite. What a wonderful professional location. It's very accessible. I bet potential clients are really impressed by the selection of u-hauls when they make their way to meet Mr. CEO Brian Thom in the u-haul showroom and discuss business. You can see all the effort into finding business partners at this serious operation. A whole lot of constructive activity must be getting done at UHP. Does Thom do anything besides manipulate the price, regurgitate old PR's with a few words changed, and sell stock? What really has changed? A few names change, like a few words change, in a regurgitated PR? 3 years ago it seems Beplate had over 30 million shares. What happened to them? Why is nothing to do with this so-called company verifiable? I never see any answers into what has changed since the 2017 PMA and now. This whole thing is beyond fishy.
Transaction
Date Reported DateTime Exercisable Expiration Company Symnbol Insider Relationship Shares Traded Conversion Price Shares Owned Filing
2019-11-05 Option Award 2021-08-06 5:22 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K CEO 400,000 $0.97 712,142
(Direct) View
2021-01-06 Option Award 2021-01-11 4:30 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K Director 10% Owner 30,730,000 $0.56 35,805,142 (Direct) View
2020-11-30 Option Award(A) 2020-12-04 5:00 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K Former CEO 40,000 $0 360,000
(Direct) View
2020-11-30 Option Award 2020-12-02 5:00 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K Former CEO 40,000 $0 311,444
(Direct) View
2020-09-30 Option Award 2020-11-20 4:00 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K Chief Executive Officer 147,750 $0 390,000
(Direct) View
2020-07-21 Option Award 2020-07-30 7:46 pm N/A N/A United Health Products Inc. UEEC BEPLATE DOUGLAS K Chief Executive Officer 5,070,000 $0.71 5,075,142
(Direct) View
https://www.secform4.com/insider-trading/1256745.htm
As unthinkable as it is, maybe your word Beplate has nothing to do with this is not very believable. It's just hard to believe someone with so many shares in a non-existent enterprise is not lurking about.
Are they honest individuals? Can UHP be trusted? It's very relevant Mr. Con Man. And it is the point. Is it intelligent to trust this operation with your hard earned money? Is someone an idiot, as you proclaim, if they do not want to entrust this type of individual with their money?
https://www.sec.gov/files/litigation/complaints/2022/comp25413.pdf
Idiot!
There are NO outstanding suits against the company! Period!
The SEC views these fraudulent actors differently than you. And you have no problem with defrauding shareholders when they are getting conned out of money. But you do have a problem with people, with common sense, pointing out to others what the lowlifes are trying to do with them and their money. UHP might be heroes to you.To the SEC, not so much. Go ahead, keep telling everyone this is business as normal (maybe in a Ponzi Scheme).
"FIRST CLAIM FOR RELIEF
Violations of Exchange Act Section IO(b) and Rule 10b-5 Thereunder
(UHP and Beplate)
SECOND CLAIM FOR RELIEF
Violations of Exchange Act Section I0(b) and Rules IOb-S(a) and (c) Thereunder
(Schiliro)
THIRD CLAIM FOR RELIEF
Aiding and Abetting Violations of Exchange Act Section lO(b) and Rule 10b-5(b)
(Schiliro)
FOURTH CLAIM FOR RELIEF
Violations of Securities Act Section 17(a)
(All Defendants)
FIFTH CLAIM FOR RELIEF
Violations of Exchange Act Section 13(a), 13(b)(2)(A) and 13(b)(2)(B)
of the Exchange Act and Rules 12b-20, 13a-1 and 13a-13 Thereunder
(UHP)
SIXTH CLAIM FOR RELIEF
Aiding and Abetting Violations of Exchange Act Section 13(a),
13(b)(2)(A), 13(b)2)B), and Rules 12b-20, 13a-1 and 13a-13
(Beplate and Schiliro)
SEVENTH CLAIM FOR RELIEF
Violation of Section 13(b)(5) of the Exchange Act and Exchange Act Rule 13b2-1
(Beplate and Schiliro)
EIGHTH CLAIM FOR RELIEF
Violations of Exchange Act Section 13(a) and Rule 13a-14 Thereunder
(Beplate)
NINTH CLAIM FOR RELIEF
Violations of Rule 13b2-2 of the Exchange Act
(Beplate and Schiliro)
TENTH CLAIM FOR RELIEF
Violations of Sarbanes-Oxley Act Section 304(a)
(Beplate)
ELEVENTH CLAIM FOR RELIEF
Violations of Exchange Act Section 16(a) and Rule 16a-3 Thereunder
(Beplate)
What happened with the 2017 submission? It's relevant. https://www.otcmarkets.com/filing/html?id=12414685&guid=4td-kaJ6H_M4B3h#UEEC_EX991_HTM
Nothing could be more relevant than what happened. Only a complete fool would pass this off (which is what you fish for).
"FDA Selects HemoStyp ® for CtQ Pilot Program
Henderson, Nevada – December 4, 2017 –United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the FDA’s new and innovative CtQ Pilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meeting with FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).
The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics of the device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the postmarket inspection. For pilot program participants, the FDA would forego conducting the standard PMA preapproval inspection, and a postmarket inspection focusing on the PMA applicant’s implementation of the critical to quality characteristics would be conducted instead.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner. This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html)
Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application – Expanded Indication submission with the US FDA-- continues to progress, and is in an advanced stage of review
About Premarket Approval Application Critical to Quality (PMA CtQ) Pilot Program
Top-quality medical devices help the FDA better protect and promote public health. And one of the top priorities for FDA’s medical devices center is a focus on quality.
More specifically, the FDA is working with stakeholders—industry, health care providers, patients, payers, and investors—to build a strong Case for Quality.
This program allows the FDA to identify device manufacturers that consistently produce high-quality devices. By doing so, we can better focus our resources helping other manufacturers raise their level of quality. This program also helps the FDA identify and promote practices that support consistent quality manufacturing, and align our regulatory, enforcement, compliance approaches with those practices.
The FDA launched the Case for Quality in 2011 following an in-depth review of device quality data and feedback from both FDA and industry stakeholders. The FDA’s analysis flagged certain widespread or common manufacturing risks that impact product quality. The review also showed manufacturers that focus on and manage those risks often become more productive, receiving fewer complaints, needing to open fewer CAPAs and investigations, and having lower quality-related product costs than their competitors.
In simple terms, the review identified that an investment in quality has long-term payoffs."
I’m no con man, you are doing what you always do which is PROJECTION! I’m an informed investor. You see dirtbag, I was in the business for 36 years and retired in an executive position from a 17 billion dollar pharmaceutical company. I know what it takes, by just reading a clinical study, to know if it has any potential for FDA approval and, this product will get approved! It was “my business” to know this! I do not work for the company, categorically, and I never have.
You on the other hand, try to create confusion with posts that are clearly old news or by using misleading content to “twist” the narrative to create unfounded fear in the legitimacy of this story. You try to get investors to sell so that you, the SHORT SELLER” can make money.
The very fact that you can try and disenfranchise investors with a positive like the full FDA submission is telling in and of itself. You are not legitimate and what you do-is an abject lie, a failure and totally fraudulent!
The people that remain on this board are longs that have been here from the beginning and you will never have any effect on them you’re totally misleading to regular investors in this stock.
You are the worst that humanity has to offer when it comes to honesty, integrity and character!
Get a U-Haul from UHP 🚽headquarters🧻. It'll make you feel better because you will be visiting such a nice suite. 526 Commerce Circle, Suite 120 Mesquite, NV 89027
Specifically what have I misstated 🍭Mr. Con Man🍭? You seem to have a dislike for anyone who displays an ounce of common sense. And believe me, it doesn't take much to see through this Ponzi Scheme with the mountain of misinformation; every bit of it unverifiable. All I ever see you do is fish for suckers, groom them into your internet boiler room, defraud them, and then recruit them into the base of the Ponzi Scheme relieving them of their hard earned money..
Name a single time you have been right about anything in many, many years posting about this stock. Every time I read a post by you, the exact opposite of what you are describing becomes reality.
Utter bullshit. There is no link or verification whatsoever. It is truly amazing the way you provide manufactured bullshit and attempt to pass it off as fact.
ONLY facts matter! The fact is UEEC was assisted by a third party consultant RCA in packaging the PMA eSTAR submission. RCA is staffed by numerous former FDA employees and the FDA made a selection of UEEC to utilize the new eSTAR module for a reason! The fluff bs and posts by a bunch of unemployed bashers certainly does not matter!
$5-$10++
I'll tell you what though, that is an unbelievably beautiful spot, even if one doesn't like the desert.
Apparently, they rent a po box in a rental space office. Lots of companies do that. However, it's not even probable they have actual office space there. They just rent the box to look like a real company.
The whole company is run out of rodmans basement and promoted on chat boards across the internet. Nothing to see or buy from here. All you can buy is his stock.
EDIT:.. OH oh, I take it back. Turn around and you see a truck and hilo. That is this months incoming stock of bandaids that uhp made for China. I really hate to be wrong about a company.
Just kidding.🤣
UHP Headquarters: 526 Commerce Circle, Suite 120 Mesquite, NV 89027 Try and find office space. I cannot. Is there anything more than a PO Box? Zoom in on the map view and it shows building numbers. This appears to be a local U-Haul dealer using the building. You can click on different building and check the photos too. It calls this headquarters on the UHP website. And this so-called "company" is going to compete with J&J Surgicell and Phizer Oxycel among others? No wonder there have never been any sales.
Concur. Someone had posted a June decision window; I think that 90 day processing is the correct assessment;
that puts June 21 in play (or earlier). Lets hope political nit picking does not surface hindering a valuable resource
to the medical communities. Of course there is no guarantee of approval; but I like our possibilities.
My plan; continue to pick up shares on the cheap; so Sellers keep unloading and I will be buying as $ permits.
Today's sellers will be faced with a day of intense regret (I project).
Utter nonsensical bullshit. 🚽Hemoshit🍭 marketed over a decade ago and is always a dismal failure at every level. This totally failed FDA scrutiny and approval years ago:
https://www.otcmarkets.com/filing/html?id=12414685&guid=4td-kaJ6H_M4B3h#UEEC_EX991_HTM.
The POS band aid could not even sell over the counter with the degenerate con men running the company defrauding shareholders about having a market:
https://www.sec.gov/files/litigation/complaints/2022/comp25413.pdf.
There isn't any evidence this so called company is anything more than an internet boiler room Ponzi Scheme. Here was the head of the con game 11 years ago telling people what would happen in 2014, a cool decade ago: What happened? Nothing as always...one bullshit bait & switch PR after another with nothing more than internet con men hyping it,
Can't wait for the day we read the headlines about "United Health Product Hemostyp Gauze" saves lives and they call it a miracle! Medical community headline Hemostyp Gauze saved a life today!
$5-$10++
Regurgitate the 🚽bait_&_switch🍭 contracts, deals, and partnerships
https://seekingalpha.com/article/4300303-united-health-products-press-releases-cannot-be-taken-face-value
Another pr and this horse will run!!
$5-$10++
Sounds great! Molto bene!
I think we would get a much better deal if we buy 3 villas, Trust, DR5, and Band Aid.
News news and more news popping up in searches!
https://markets.businessinsider.com/news/stocks/united-health-products-submits-full-fda-pma-application-1033184659
$5-$10++
"So let’s do the math"
CHARLIESAN
Re: rodman post# 12756
Tuesday, December 19, 2023 12:11:04 PM
Post # 12757 of 13297
Yes, I am a loser; about 800K in this position; and I own a significant amount of shares; in the 7 digits. You must be braindead to think that this CEO and management team do not deserve criticism in their inability to get a PMA filed. They need prodded; pushed; criticized; by any means necessary to accomplish
their duties. So you will stand by another year and watch paint dry? Their communication and actions are a travesty and reek of incompetence. Calling it like it is. If you cannot see this you might look in the mirror before denigrating others.
"So let’s do the math
You buy now at .20 biggest downside is .20
You don’t own any shares.. You put $3000-$5000 into UEEC worse case scenario you lost a few bucks…
FDA approval comes in and you’re looking at 3000-5000% profit easily…
Agree???
I would say it’s a no brainer
Disclosure I’ve been adding to my position on dips"
It already failed FDA approval: https://www.otcmarkets.com/filing/html?id=12414685&guid=4td-kaJ6H_M4B3h#UEEC_EX991_HTM
"FDA Selects HemoStyp ® for CtQ Pilot Program
Henderson, Nevada – December 4, 2017 –United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the FDA’s new and innovative CtQ Pilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meeting with FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).
The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics of the device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the postmarket inspection. For pilot program participants, the FDA would forego conducting the standard PMA preapproval inspection, and a postmarket inspection focusing on the PMA applicant’s implementation of the critical to quality characteristics would be conducted instead.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner. This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html)
Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application – Expanded Indication submission with the US FDA-- continues to progress, and is in an advanced stage of review
About Premarket Approval Application Critical to Quality (PMA CtQ) Pilot Program
Top-quality medical devices help the FDA better protect and promote public health. And one of the top priorities for FDA’s medical devices center is a focus on quality.
More specifically, the FDA is working with stakeholders—industry, health care providers, patients, payers, and investors—to build a strong Case for Quality.
This program allows the FDA to identify device manufacturers that consistently produce high-quality devices. By doing so, we can better focus our resources helping other manufacturers raise their level of quality. This program also helps the FDA identify and promote practices that support consistent quality manufacturing, and align our regulatory, enforcement, compliance approaches with those practices.
The FDA launched the Case for Quality in 2011 following an in-depth review of device quality data and feedback from both FDA and industry stakeholders. The FDA’s analysis flagged certain widespread or common manufacturing risks that impact product quality. The review also showed manufacturers that focus on and manage those risks often become more productive, receiving fewer complaints, needing to open fewer CAPAs and investigations, and having lower quality-related product costs than their competitors.
In simple terms, the review identified that an investment in quality has long-term payoffs."
So let’s do the math
You buy now at .20 biggest downside is .20
You don’t own any shares.. You put $3000-$5000 into UEEC worse case scenario you lost a few bucks…
FDA approval comes in and you’re looking at 3000-5000% profit easily…
Agree???
I would say it’s a no brainer
Disclosure I’ve been adding to my position on dips
SHOONDALE is in full panic mode now.
And the worst part, his two alter egos have also abandoned him:
SCUMBAG FRAUDSTERS = BOOTED FROM I-HUB
ZORAX = ABANDONED HIM
Time to switch up aliases again SHOON.
Hey Band Aid, can I carry your bags in Italy?
Trust, im going to Italy in September to scope things out. Do you think I will have the brinks truck deliver my payload by then?
Getting ready to buy my Island place along with Italy. Bye, bye non believing trolls.
Getting ready to buy my Island place along with Italy. Bye, bye non believing trolls.
Man, you crack me up! Do you get paid by the post or by the word. What a miserable life you’ve picked for yourself. While you’re spewing your lies I’m buying!
Hand over fist!
OLD NEWS, DUMMY! That’s been settled back in ‘22. Clean slate now!!!! What an absolute idiot you are!
Those are the insiders unloading at this unrealistically high price. There is nothing but a sham product that has failed at every level, no revenues, and no functional business.
Hey Chris, lately I’ve been fed up with the lies from “shoonshortseller”. I’ve been dumping on him and am gonna just ignore…for now. BTW, I’ve been adding to my position and accumulating even more shares and enjoying every buy!
There are only PONZI SCHEME OPERATORS!!! on this board so ignore common sense!!
Fixed it for you/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |